The National Times - US approves first pill for treatment of alopecia

US approves first pill for treatment of alopecia


US approves first pill for treatment of alopecia
US approves first pill for treatment of alopecia / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File

The Food and Drug Administration on Monday approved a drug called baricitinib as the first oral tablet for treating severe alopecia areata, an autoimmune disorder affecting more than 300,000 people in the United States every year.

Change text size:

Alopecia causes either temporary or permanent patchy hair loss that can affect any hair-bearing site of the body, leading to emotional distress. The condition has come to the fore recently through high-profile cases including Hollywood actress Jada Pinkett Smith and congresswoman Ayanna Pressley.

"Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia," said FDA official Kendall Marcus in a statement.

"Today's approval will help fulfill a significant unmet need for patients with severe alopecia areata."

Baricitinib, which is made by US pharmaceutical company Eli Lilly and known by the trade name Olumiant, belongs to a class of drugs called Janus kinase inhibitors. It works by interfering with the cellular pathway that leads to inflammation.

Its approval for use against alopecia was based on the results of two randomized, controlled clinical trials involving a total 1,200 adults with severe alopecia.

Each trial split participants into three groups: a placebo group, a group that received a two-milligram dose every day, and a group that received a four-milligram dose every day.

After 36 weeks, almost 40 percent of those on the higher dose grew back 80 percent of their scalp hair, compared to around 23 percent of the lower dose group, and five percent of the placebo group.

Around 45 percent of people in the higher dose group also saw significant eyebrow and eyelash regrowth.

The most common side effects included upper respiratory tract infections, headaches, acne, high cholesterol, and increase of an enzyme called creatinine phosphokinase.

Prior treatments for alopecia included topical or oral drugs, but these have been considered experimental and none was approved.

Baricitinib was previously approved for treatment of rheumatoid arthritis, and during the Covid pandemic its license was extended to the treatment of hospitalized Covid patients.

S.M.Riley--TNT

Featured

Teen Gun Violence Survivor Spends Three Years in St. Louis Hospital

Jaloni, a survivor of gun violence in St. Louis, spent more than 475 days across three years living in SSM Health Cardinal Glennon Children’s Hospital. With no safe place to go and family unable to provide care, the teen turned his hospital room into a home, illustrating the growing national issue of children remaining in hospitals beyond medical necessity.

Nursing Leaders Warn HSE Recruitment Controls Are Unsafe

More than 130 senior nursing and midwifery managers in Ireland have formally warned the Department of Health that new Health Service Executive (HSE) recruitment controls are unsafe and unworkable. In a letter to the department’s secretary-general, the leaders argued that mandatory approval processes for new hires obstruct essential staffing, undermine professional judgment, and expose both patients and staff to foreseeable harm.

Make-A-Wish Announces 2026 Starblazer Award Honorees; Allied World Becomes First Corporate Founder

Make-A-Wish has announced the nine recipients of its 2026 Starblazer Awards, honoring wish alumni who continue to inspire positive change in their communities. The organization also confirmed that Allied World has become the first corporate award founder for the national program with a $1 million commitment.

Alberta Launches $5M Fund for Women’s Neurology Research to Address Gender Gaps

The Government of Alberta has launched its inaugural "Closing the Gap" campaign, allocating $5 million to support sex-specific medical research with a primary focus on women’s neurological health. While local experts and researchers have welcomed the initiative as a critical step toward addressing historical disparities, they caution that lasting change requires sustained, multi-specialty investment beyond this initial round.

Change text size: